National Institutes of Health to Grant Exclusive Patent License to Generation Bio and Spark Therapeutics for AAV Vectors

Summary

The National Heart, Lung and Blood Institute is considering granting Generation Bio, a Massachusetts-based company, an exclusive patent license to practice AAV vectors, and a co-exclusive license to Generation Bio and Spark Therapeutics, a Pennsylvania-based company, for the production and delivery of genes using these vectors.